Compare EVC & VCRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | EVC | VCRE |
|---|---|---|
| Founded | 1996 | N/A |
| Country | United States | Sweden |
| Employees | N/A | N/A |
| Industry | Broadcasting | |
| Sector | Industrials | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 335.0M | 316.4M |
| IPO Year | 2000 | 2026 |
| Metric | EVC | VCRE |
|---|---|---|
| Price | $8.61 | $10.78 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 1.2M | 8.7K |
| Earning Date | 05-05-2026 | N/A |
| Dividend Yield | ★ 5.35% | N/A |
| EPS Growth | ★ 47.59 | N/A |
| EPS | ★ 0.32 | N/A |
| Revenue | ★ $536,034,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $26.16 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.95 | $10.47 |
| 52 Week High | $13.74 | $13.15 |
| Indicator | EVC | VCRE |
|---|---|---|
| Relative Strength Index (RSI) | 43.70 | 45.84 |
| Support Level | $7.72 | $10.75 |
| Resistance Level | $10.09 | $13.00 |
| Average True Range (ATR) | 0.36 | 0.63 |
| MACD | 0.13 | 0.04 |
| Stochastic Oscillator | 88.37 | 38.81 |
Entravision Communications Corp owns and operates Spanish language television and radio stations in the United States. The Company also owns and operates a smaller group of television stations that broadcast English language programming and has operations that provide programmatic advertising technology and services. The Company has organized its operations into two reportable segments. Its media segment includes its television, radio, and digital marketing operations. Its advertising and technology services segment provides programmatic advertising and technology services. The company generates the majority of its revenue from the advertising and technology services segment. Geographically, the company generates the majority of its revenue from the United States.
Vicore Pharma Holding AB is a clinical-stage biopharmaceutical company developing a new class of disease-modifying therapies for respiratory and fibrotic diseases, including idiopathic pulmonary fibrosis (IPF). Its main program, buloxibutid, is an oral angiotensin II type 2 receptor agonist that has received Orphan Drug and Fast Track designation from the U.S. Food and Drug Administration and is currently being evaluated in the 52-week Phase 2b ASPIRE trial in IPF. Currently, Vicore is operating mainly in Sweden.